Tobias Arkenau retweeted
Explore the cutting-edge of lung cancer treatment with @EllipsesCMO. Learn about the latest breakthroughs in clinical trials and the growing demand for next-generation therapies. Read more: pharmafocus.com/collections/… #LungCancer #PrecisionMedicine #Innovation #EllipsesPharma
Tobias Arkenau retweeted
AS SEEN ON TV: Learn about our role in advancing Precision Medicine and how we validate promising assets through our Scientific Advisory Group. Check out the interview: ellipses.life/ellipses-pharm… #PrecisionMedicine #EllipsesPharma
Tobias Arkenau retweeted
EP0031, our next-gen RET inhibitor, receives FDA Orphan Drug Designation. A crucial step in advancing cancer treatments. #OrphanDrug #EP0031 #EllipsesPharma ellipses.life/ellipses-ep003…
Tobias Arkenau retweeted
📄 Access the poster presentation for Asset EP0031, shared by @EllipsesCMO at @AACR Boston. Dive into the details and join us in advancing cancer research!💡ellipses.life/wp-content/upl…
#AACR2023 #CancerInnovation 🚀
Tobias Arkenau retweeted
#Targets23 Great work from Drs. @AriMarinel @mihaela_aldea and others on characterizing outcomes in #RET NSCLC post progression on selective inhibitors: patterns of progression, response to subsequent lines of therapy. – at Huntington Avenue - Prudential Center, Boston
Tobias Arkenau retweeted
I was happy to see Dr. @ElenaGarralda again - presenting work on EP0031, a next generation #RET inhibitor with impressive efficacy after selective RET inhibitors and CNS efficacy. #Targets23
Tobias Arkenau retweeted
Ellipses Announces FDA Clearance of IND Application for EP0031 for Patients With ... - goo.gl/alerts/1QWMK #GoogleAlerts #RETcancer #Lungcancer #researchmaters
Tobias Arkenau retweeted
The burden of bureaucracy in clinical research has increased for investigators & clinical research teams. ESMO proposes a framework to streamline clinical research & reduce the bureaucracy in clinical trials, promoting better care for cancer patients.
🔗annalsofoncology.org/article…
1/ Bureaucracy is overwhelming Clinical Research!
ESMO proposes principles to improve Sponsoring and Monitoring of Clinical Trials and promote patient welfare
Follow thread for examples & proposals, share if you agree!
#StreamlineClinicalResearch
@myESMO
bit.ly/3XZ63WY
Tobias Arkenau retweeted
We are excited to share our latest cancer research insights through more than 140 abstracts and presentations at #ASCO22. Read about where you can find our scientific experts at this year’s annual meeting. sarahcannon.com/about/newsro…
Tobias Arkenau retweeted
Excited to be on our first call for the new @ASCO monthly plenary series.
See attached for dates of presentations and submissions. Exciting to get data out there within 5-6 weeks of submission.
Monthly Plenary Series | ASCO asco.org/meetings-education/…
Tobias Arkenau retweeted
Be the first to hear the latest HemOnc news and best practice from the world’s leading experts 👨🔬👩🔬 Stay tuned for videos, podcasts and articles published live from the latest virtual meetings!
#HemOnc #Leusm #Lymsm #MMSM #MDSsm #MPNsm #BMTsm #CTSM #ImmunoOnc #BleedingDisorders
Tobias Arkenau retweeted
Happy Fourth of July! Wishing you a safe and enjoyable holiday with friends and family. #July4th
Tobias Arkenau retweeted
🕙 Just 10 days to go until ESMO #WorldGI2021 starts and @VJOncology are excited to report on the biggest news from the meeting
Check out 👉 vjoncology.com 👈 for exclusive interviews, podcasts and more!
@myESMO #CRCSM #HPBCsm #STCsm #ESOCsm #GICancer #ayacsm
Tobias Arkenau retweeted
Enjoying the gastrointestinal cancer oral abstract session? 🤔
Register to our upcoming #VJSession, a roundtable discussion on the latest learnings in GI from #ASCO21
Register here ➡️tinyurl.com/the-gi-session
@ASCO @OncoAlert #GIsm
Tobias Arkenau retweeted
Register now for @VJOncology's post-ASCO VJSessions!
Join us for a series of roundtable discussions with #oncology experts to review key highlights from #ASCO21
Click for more details 👇👇
GI: tinyurl.com/GI-session
GU: tinyurl.com/gu-sessions
Breast: tinyurl.com/breast-sessions
Tobias Arkenau retweeted
#MCCRWorkshop The Workshop is organised by @EORTC @myESMO and @AACR and has provided training to over 1800 investigators from all over the world since its’ inception in 1999. Apply NOW eortc.org/mccr #clinicaltrialdesign #clinicaltrials
Tobias Arkenau retweeted
Outstanding program this weekend! @BandVsCancer
This afternoon, we kick off Sarah Cannon’s 24th Annual Scientific Meeting by taking a look back at scientific advancements with the ‘Year In Review’ session lead by @deehubie @BurrisSkip and @dave6408
Tobias Arkenau retweeted
Did you know that Sarah Cannon enrolls more than 3,000 patients per year on clinical trials? We are so grateful to these patients who are helping to advance science & transform care for people facing cancer. Learn more at SarahCannon.com. #NationalHealthQualityWeek
Tobias Arkenau retweeted
Debating rectal cancer management #EIOC2020 @geriradonc @Shaheenah1 @agrothey @SirohiBhawna #globalpanel @MedDirSCRI – at Lebanon

































